Skip to Content
Merck
CN
All Photos(1)

Key Documents

View All Documentation

Safety Information

890809P

Avanti

Trehalose monooleate

Avanti Research™ - A Croda Brand 890809P, powder

Synonym(s):

D-(+)-trehalose 6-monooleate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C30H54O12
CAS Number:
338733-38-3
Molecular Weight:
606.74
UNSPSC Code:
12352211
NACRES:
NA.25

form

powder

packaging

pkg of 1 × 10 mg (890809P-10mg)

manufacturer/tradename

Avanti Research™ - A Croda Brand 890809P

shipped in

dry ice

storage temp.

−20°C

SMILES string

O[C@H]([C@@H](COC(CCCCCCC/C=C\CCCCCCCC)=O)O[C@H](O[C@@H](O[C@@H]([C@H]([C@@H]1O)O)CO)[C@@H]1O)[C@@H]2O)[C@@H]2O

InChI

1S/C30H54O12/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-22(32)39-19-21-24(34)26(36)28(38)30(41-21)42-29-27(37)25(35)23(33)20(18-31)40-29/h9-10,20-21,23-31,33-38H,2-8,11-19H2,1H3/b10-9-/t20-,21-,23-,24-,25+,26+,27-,28-,29-,30-/m1/s1

InChI key

MLVMMWOWJSIKLS-WYVBACLFSA-N

Biochem/physiol Actions

Trehalose monooleate is derived from sugar and fatty acid moieties. It is found to possess anti-aggregation activity. Trehalose monooleate has a sustaining effect against agitation and heat stress in protein. It is considered nonhemolytic and nontoxic. Trehalose monooleate is employed in solid lipid nanoparticles for treating psoriasis.

Packaging

5 mL Amber Glass Screw Cap Vial (890809P-10mg)

Other Notes

For R&D use only. Not for drug, household, or other uses.

Legal Information

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Regulatory Information

监管及禁止进口产品

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Nanomaterials for Clinical Applications: Case Studies in Nanomedicines, 17-17 (2020)
Smita S Kale et al.
Molecular pharmaceutics, 13(12), 4082-4093 (2016-10-12)
Protein aggregation is a major problem of therapeutic proteins because aggregation decreases their therapeutic activity and shelf life and induces immunogenicity. Stabilization against aggregation is commonly attained by addition of different excipients like sugars, surfactants, buffers, salts, amino acids, polymers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service